ConductScience.org, home

Paper37843751

Multicenter prospective phase II trial of concurrent chemoradiotherapy with weekly low-dose carboplatin for cisplatin-ineligible patients with advanced head and neck squamous cell carcinoma.

Ueki Y and 15 others. Int J Clin Oncol, 2024. Cited by 5 papers, by iCite.

Cite this record

ConductScience Library. Multicenter prospective phase II trial of concurrent chemoradiotherapy with weekly low-dose carboplatin for cisplatin-ineligible patients with advanced head and neck squamous cell carcinoma. Papers, record 37843751. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37843751

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Multicenter prospective phase II trial of concurrent chemoradiotherapy with weekly low-dose carboplatin for cisplatin-ineligible patients with advanced head and neck squamous cell carcinoma.
PubMed
Journal
Int J Clin Oncol
PubMed
Year
2024
PubMed
Publication types
Clinical Trial, Phase II, Multicenter Study, Journal Article
PubMed
Citations, by iCite
5
iCite
Relative citation ratio, by iCite
1.09, provisional
iCite
Revised in PubMed
2026-10-31
PubMed

Authors16

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Ueki YYushihttps://orcid.org/0000-0002-1699-7891
2Ohshima SShusuke
3Yokoyama YYusuke
4Takahashi TTakeshi
5Shodo RRyusuke
6Yamazaki KKeisuke
7Ohtaki KKohei
8Saijo KKohei
9Tanaka RRyoko
10Togashi TTakafumi
11Sato YYuichiro
12Takano SSatoshi
13Omata JJo
14Takahashi NNao
15Okabe RRyuichi
16Horii AArata

Source PubMed

Download CSV of authors

Topics13

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Head and Neck NeoplasmsMajor topic
Carcinoma, Squamous CellMajor topic
Adult
Male
Humans
Aged
Female
Cisplatin
Squamous Cell Carcinoma of Head and Neck
Carboplatin
Prospective Studies
Chemoradiotherapy
Antineoplastic Combined Chemotherapy Protocols

Source PubMed

Download CSV of topics

References21

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
119097774New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).Eur J Cancer2009https://conductscience.org/library/papers/19097774PubMed
217467265Chemoradiation comparing cisplatin versus carboplatin in locally advanced nasopharyngeal cancer: randomised, non-inferiority, open trial.Eur J Cancer2007https://conductscience.org/library/papers/17467265PubMed
331893516Head and Neck Cancer.N Engl J Med2020https://conductscience.org/library/papers/31893516PubMed
433538338Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.CA Cancer J Clin2021https://conductscience.org/library/papers/33538338PubMed
535230884Weekly Cisplatin Plus Radiation for Postoperative Head and Neck Cancer (JCOG1008): A Multicenter, Noninferiority, Phase II/III Randomized Controlled Trial.J Clin Oncol2022https://conductscience.org/library/papers/35230884PubMed
623208313Investigation of the freely available easy-to-use software 'EZR' for medical statistics.Bone Marrow Transplant2013https://conductscience.org/library/papers/23208313PubMed
726712252Clinical recommendations for defining platinum unsuitable head and neck cancer patient populations on chemoradiotherapy: A literature review.Oral Oncol2016https://conductscience.org/library/papers/26712252PubMed
829567334Multicenter phase I/II study of chemoradiotherapy with high-dose CDDP for head and neck squamous cell carcinoma in Japan.Auris Nasus Larynx2018https://conductscience.org/library/papers/29567334PubMed
99552032Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study.J Clin Oncol1998https://conductscience.org/library/papers/9552032PubMed
1025442075Chemoradiation in elderly patients with head and neck cancers: a single institution experience.Am J Otolaryngol2015https://conductscience.org/library/papers/25442075PubMed
1136136306Cetuximab-Based vs Carboplatin-Based Chemoradiotherapy for Patients With Head and Neck Cancer.JAMA Otolaryngol Head Neck Surg2022https://conductscience.org/library/papers/36136306PubMed
1214645636Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer.N Engl J Med2003https://conductscience.org/library/papers/14645636PubMed
1310758304The use of carboplatin and paclitaxel with daily radiotherapy in patients with locally advanced squamous cell carcinomas of the head and neck.Int J Radiat Oncol Biol Phys2000https://conductscience.org/library/papers/10758304PubMed
1412506176An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.J Clin Oncol2003https://conductscience.org/library/papers/12506176PubMed
1521900218Esophageal and esophagogastric junction cancers.J Natl Compr Canc Netw2011https://conductscience.org/library/papers/21900218PubMed
1626423341Safety and efficacy of concurrent carboplatin plus radiotherapy for locally advanced head and neck cancer patients ineligible for treatment with cisplatin.Jpn J Clin Oncol2015https://conductscience.org/library/papers/26423341PubMed
172681557Carboplatin dosage: prospective evaluation of a simple formula based on renal function.J Clin Oncol1989https://conductscience.org/library/papers/2681557PubMed
1825601342
Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
Lancet Oncol2015https://conductscience.org/library/papers/25601342PubMed
1916467544Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.N Engl J Med2006https://conductscience.org/library/papers/16467544PubMed
2022646630Preoperative chemoradiotherapy for esophageal or junctional cancer.N Engl J Med2012https://conductscience.org/library/papers/22646630PubMed

See all 21 referencesDownload CSV of references

Cited by4

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 5 citations.

PMIDTitleJournalYearIn PapersSource
40652131Oropharyngeal candidiasis during radiotherapy for head and neck cancer: an observational study on prevalence, pain, and risk factors.Eur Arch Otorhinolaryngol2025https://conductscience.org/library/papers/40652131PubMed
40323514Concurrent chemoradiotherapy with weekly low-dose carboplatin for cisplatin-ineligible patients with head and neck squamous cell carcinoma: survival analysis based on 2-year follow-up data.Int J Clin Oncol2025https://conductscience.org/library/papers/40323514PubMed
39235658The role of prehabilitation in HNSCC patients treated with chemoradiotherapy.Support Care Cancer2024https://conductscience.org/library/papers/39235658PubMed
39093329Treatment options for cisplatin-ineligible patients with locally advanced head and neck squamous cell carcinoma: a systematic review.J Cancer Res Clin Oncol2024https://conductscience.org/library/papers/39093329PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/37843751

GET https://conductscience.org/api/papers/v1/37843751/references?page=2